|Trade names||M-M-R II, Priorix, Tresivac, others|
|Other names||MPR vaccine|
|AHFS/Drugs.com||Professional Drug Facts|
|(what is this?)|
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses. After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended for those who do not have evidence of immunity, those with well-controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection.
The MMR vaccine is widely used around the world, with over 500 million doses having been given in over 100 countries as of 2001. Measles resulted in 2.6 million deaths per year before immunization became common. This has decreased to 122,000 deaths per year as of 2012[update], mostly in low-income countries. Through vaccination, as of 2018[update], rates of measles in North and South America are very low. Rates of disease have been seen to increase in populations that go unvaccinated. Between 2000 and 2016, vaccination decreased measles deaths by a further 84%.
Side effects of immunization are generally mild and go away without any specific treatment. These may include fever, as well as pain or redness at the injection site. Severe allergic reactions occur in about one in a million people. Because it contains live viruses, the MMR vaccine is not recommended during pregnancy but may be given while breastfeeding. The vaccine is safe to give at the same time as other vaccines. Being recently immunized does not increase the risk of passing measles, mumps, or rubella on to others. Vaccination does not increase the risk of autism. The MMR vaccine is a mixture of live weakened viruses of the three diseases.
The MMR vaccine was developed by Maurice Hilleman. It was licensed for use in USA by Merck in 1971. Stand-alone measles, mumps, and rubella vaccines had been previously licensed in 1963, 1967, and 1969, respectively. Recommendations for a second dose were introduced in 1989. The MMRV vaccine, which also covers chickenpox, may be used instead. An MR vaccine, without coverage for mumps, is also occasionally used.
In 2020, Cochrane concluded "Existing evidence on the safety and effectiveness of MMR vaccine supports current policies of mass immunisation aimed at global measles eradication and in order to reduce morbidity and mortality associated with mumps and rubella."
The combined MMR vaccine induces immunity less painfully than three separate injections at the same time, and sooner and more efficiently than three injections given on different dates. Public Health England reports that providing a single combined vaccine as of 1988, rather than giving the option to have them also done separately, increased uptake of the vaccine.
Before the widespread use of a vaccine against measles, rates of disease were so high that infection was felt to be "as inevitable as death and taxes." Reported cases of measles in the United States fell from hundreds of thousands to tens of thousands per year following introduction of the vaccine in 1963. Increasing uptake of the vaccine following outbreaks in 1971, and 1977, brought this down to thousands of cases per year in the 1980s. An outbreak of almost 30,000 cases in 1990 led to a renewed push for vaccination and the addition of a second vaccine to the recommended schedule. Fewer than 200 cases have been reported in the U.S. each year between 1997 and 2013, and the disease is no longer considered endemic there.
The benefit of measles vaccination in preventing illness, disability, and death has been well documented. The first 20 years of licensed measles vaccination in the U.S. prevented an estimated 52 million cases of the disease, 17,400 cases of intellectual disability, and 5,200 deaths. During 1999–2004, a strategy led by the World Health Organization and UNICEF led to improvements in measles vaccination coverage that averted an estimated 1.4 million measles deaths worldwide. Between 2000 and 2013, measles vaccination resulted in a 75% decrease in deaths from the disease.
Measles is common in many areas of the world. Although it was declared eliminated from the U.S. in 2000, high rates of vaccination and good communication with persons who refuse vaccination are needed to prevent outbreaks and sustain the elimination of measles in the U.S. Of the 66 cases of measles reported in the U.S. in 2005, slightly over half were attributable to one unvaccinated individual who acquired measles during a visit to Romania. This individual returned to a community with many unvaccinated children. The resulting outbreak infected 34 people, mostly children and virtually all unvaccinated; 9% were hospitalized, and the cost of containing the outbreak was estimated at $167,685. A major epidemic was averted due to high rates of vaccination in the surrounding communities.
In 2017, an outbreak of measles occurred among the Somali-American community in Minnesota, where MMR vaccination rates had declined due to the misconception that the vaccine could cause autism. The Centers for Disease Control and Prevention recorded 65 affected children in the outbreak by April 10, 2017.
Rubella, also known as German measles, was also very common before widespread vaccination. The major risk of rubella is during pregnancy when the baby may contract congenital rubella, which can cause significant congenital defects.
Mumps is another viral disease that was once very common, especially during childhood. If mumps is acquired by a male who is past puberty, a possible complication is bilateral orchitis, which can in some cases lead to sterility.
The MMR vaccine is administered by a subcutaneous injection. The second dose may be given as early as one month after the first dose. The second dose is a dose to produce immunity in the small number of persons (2–5%) who fail to develop measles immunity after the first dose. In the U.S. it is done before entry to kindergarten because that is a convenient time. Areas where measles is common typically recommend the first dose at 9 months of age and the second dose at 15 months of age.
Adverse reactions, rarely serious, may occur from each component of the MMR vaccine. Ten percent of children develop fever, malaise, and a rash 5–21 days after the first vaccination; and 3% develop joint pain lasting 18 days on average. Older women appear to be more at risk of joint pain, acute arthritis, and even (rarely) chronic arthritis. Anaphylaxis is an extremely rare but serious allergic reaction to the vaccine. One cause can be egg allergy. In 2014, the FDA approved two additional possible adverse events on the vaccination label: acute disseminated encephalomyelitis (ADEM), and transverse myelitis, with permission to also add "difficulty walking" to the package inserts. A 2012 IOM report found that the measles component of the MMR vaccine can cause measles inclusion body encephalitis in immunocompromised individuals. This report also rejected any connection between the MMR vaccine and autism. Some versions of the vaccine contain the antibiotic neomycin and therefore should not be used in people allergic to this antibiotic.
The number of reports on neurological disorders is very small, other than evidence for an association between a form of the MMR vaccine containing the Urabe mumps strain and rare adverse events of aseptic meningitis, a form of viral meningitis. The UK National Health Service stopped using the Urabe mumps strain in the early 1990s due to cases of transient mild viral meningitis, and switched to a form using the Jeryl Lynn mumps strain instead. The Urabe strain remains in use in a number of countries; MMR with the Urabe strain is much cheaper to manufacture than with the Jeryl Lynn strain, and a strain with higher efficacy along with a somewhat higher rate of mild side effects may still have the advantage of reduced incidence of overall adverse events.
A Cochrane review found that, compared with placebo, MMR vaccine was associated with fewer upper respiratory tract infections, more irritability, and a similar number of other adverse effects.
Naturally acquired measles often occurs with immune thrombocytopenic purpura (ITP, a purpuric rash and an increased tendency to bleed that resolves within two months in children), occurring in 1 to 20,000 cases. Approximately 1 in 40,000 children are thought to acquire ITP in the six weeks following an MMR vaccination. ITP below the age of six years is generally a mild disease, rarely having long-term consequences.
False claims about autism
In 1998 Andrew Wakefield et al. published a fraudulent paper about twelve children, reportedly with bowel symptoms and autism or other disorders acquired soon after administration of MMR vaccine, while supporting a competing vaccine. In 2010, Wakefield's research was found by the General Medical Council to have been "dishonest", and The Lancet fully retracted the paper. Three months following The Lancet's retraction, Wakefield was struck off the UK medical register, with a statement identifying deliberate falsification in the research published in The Lancet, and was barred from practising medicine in the UK. The research was declared fraudulent in 2011 by the British Medical Journal.
Since Wakefield's publication, multiple peer-reviewed studies have failed to show any association between the vaccine and autism. The Centers for Disease Control and Prevention, the Institute of Medicine of the National Academy of Sciences, the UK National Health Service and the Cochrane Library review have all concluded that there is no evidence of a link.
Administering the vaccines in three separate doses does not reduce the chance of adverse effects, and it increases the opportunity for infection by the two diseases not immunized against first. Health experts have criticized media reporting of the MMR-autism controversy for triggering a decline in vaccination rates. Before publication of Wakefield's findings, the inoculation rate for MMR in the UK was 92%; after publication, the rate dropped to below 80%. In 1998, there were 56 measles cases in the UK; by 2008, there were 1348 cases, with two confirmed deaths.
In Japan, the MMR triplet is not used. Immunity is achieved by a combination vaccine for measles and rubella, followed up later with a mumps only vaccine. This has had no effect on autism rates in the country, further disproving the MMR autism hypothesis.
The component viral strains of MMR vaccine were developed by propagation in animal and human cells as all viruses require a living host cell to replicate.
For example, in the case of mumps and measles viruses, the virus strains were grown in embryonated chicken eggs. This produced strains of virus which were adapted for chicken cells and less well-suited for human cells. These strains are therefore called attenuated strains. They are sometimes referred to as neuroattenuated because these strains are less virulent to human neurons than the wild strains.
The Rubella component, Meruvax, was developed in 1967 through propagation using the human embryonic lung cell line WI-38 (named for the Wistar Institute) that was derived six years earlier in 1961.
|Disease immunized||Component vaccine||Virus strain||Propagation medium||Growth medium|
|Measles||Attenuvax||Enders' attenuated Edmonston strain||chick embryo cell culture||Medium 199|
|Mumps||Mumpsvax||Jeryl Lynn (B level) strain|
|Rubella||Meruvax II||Wistar RA 27/3 strain of live attenuated rubella virus||WI-38 human embryonic cell line||MEM (solution containing buffered salts, fetal bovine serum, human serum albumin and neomycin, etc.)|
The term "MPR vaccine" is based on the Latin names of the diseases.
Pluserix was introduced to the Hungarians in 1999. Enders’ Edmonston strain has been used since 1999 in Hungary in Merck MMR II product. GSK PRIORIX vaccine, which uses attenuated Schwarz Measles, was introduced to Hungarians in 2003.
The MMRV vaccine, a combined measles, mumps, rubella and varicella (chickenpox) vaccine, has been proposed as a replacement for the MMR vaccine to simplify administration of the vaccines. Preliminary data indicate a rate of febrile seizures of 9 per 10,000 vaccinations with MMRV, as opposed to 4 per 10,000 for separate MMR and varicella shots; U.S. health officials therefore do not express a preference for use of MMRV vaccine over separate injections.
In a 2012 study pediatricians and family doctors were sent a survey to gauge their awareness of the increased risk of febrile seizures (fever fits) in the MMRV. 74% of family doctors and 29% of pediatricians were unaware of the increased risk of febrile seizures. After reading an informational statement only 7% of family doctors and 20% of pediatricians would recommend the MMRV for a healthy 12- to 15-month-old child. The factor that was reported as the "most important" deciding factor in recommending the MMRV over the MMR+V was ACIP/AAFP/AAP recommendations (pediatricians, 77%; family physicians, 73%).
Some brands of this vaccine use gelatine, derived from domestic pigs, as a stabilizer. This has caused reduced take-up, and consequent increased levels of disease, among communities with a high proportion of Muslims or Orthodox Jews.
- Grignolio A (2018). Vaccines: Are they Worth a Shot?. Springer. p. 2. ISBN 9783319681061.
- "Measles virus vaccine / mumps virus vaccine / rubella virus vaccine (M-M-R II) Use During Pregnancy". Drugs.com. 16 October 2019. Retrieved 5 September 2020.
- "M-M-RVaxPro EPAR". European Medicines Agency. Retrieved 4 December 2020.
- "Maurice R. Hilleman, PhD, DSc". Seminars in Pediatric Infectious Diseases. 16 (3): 225–226. July 2005. doi:10.1053/j.spid.2005.05.002. PMID 16044396.
- "Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Know". U.S. Centers for Disease Control and Prevention (CDC). 26 January 2021. Retrieved 16 August 2021.
- World Health Organization (2017). "Measles vaccines: WHO position paper – April 2017". Wkly. Epidemiol. Rec. 92 (17): 205–27. hdl:10665/255149. PMID 28459148. Lay summary (PDF).
- Kinney R (2 May 2017). "Core Concepts - Immunizations in Adults - Basic HIV Primary Care - National HIV CurriculumImmunizations in Adults". www.hiv.uw.edu.
- Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L (22 May 1998). "Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR Recomm Rep. 47 (RR-8): 1–57. PMID 9639369.
- "Top 10 myths about MMR, Top 10 truths about MMR" (PDF). NHS. Retrieved 10 September 2018.
- "Addressing misconceptions on measles vaccination". European Centre for Disease Prevention and Control. Retrieved 10 September 2018.
- "Measles Fact Sheet #286". World Health Organization (WHO). Retrieved 1 December 2014.
- "MMR (Measles, Mumps, and Rubella) Vaccine Information Statement". Centers for Disease Control and Prevention (CDC). 6 August 2021. Retrieved 16 August 2021.
- Di Pietrantonj, C; Rivetti, A; Marchione, P; Debalini, MG; Demicheli, V (April 2020). "Vaccines for measles, mumps, rubella, and varicella in children". Cochrane Database of Systematic Reviews. 4: CD004407. doi:10.1002/14651858.CD004407.pub4. PMC 7169657. PMID 32309885.
- Hussain A, Ali S, Ahmed M, Hussain S (3 July 2018). "The Anti-vaccination Movement: A Regression in Modern Medicine". Cureus. 10 (7): e2919. doi:10.7759/cureus.2919. PMC 6122668. PMID 30186724.
- Spencer JP, Trondsen Pawlowski RH, Thomas S (15 June 2017). "Vaccine Adverse Events: Separating Myth from Reality". American Family Physician. 95 (12): 786–794. PMID 28671426.
- Goodson, JL; Seward, JF (December 2015). "Measles 50 Years After Use of Measles Vaccine". Infectious Disease Clinics of North America. 29 (4): 725–43. doi:10.1016/j.idc.2015.08.001. PMID 26610423.
- "Measles: information about the disease and vaccines Questions and Answers" (PDF). Immunization Action Coalition. Retrieved 10 September 2018.
- "Information Sheet Observed Rate of Vaccine Reactions, Measles, Mumps, and Rubella Vaccines" (PDF). World Health Organization (WHO). May 2014. Retrieved 10 September 2018.
- "Measles, mumps, rubella (MMR): use of combined vaccine instead of single vaccines". GOV.UK. Retrieved 12 July 2018.
- Babbott FL Jr; Gordon JE (1954). "Modern measles". Am J Med Sci. 228 (3): 334–61. doi:10.1097/00000441-195409000-00013. PMID 13197385.
- Centers for Disease Control and Prevention (CDC) (October 1994). "Summary of notifiable diseases, United States, 1993" (PDF). MMWR Morb. Mortal. Wkly. Rep. 42 (53): i–xvii, 1–73. PMID 9247368.
- Centers for Disease Control and Prevention (CDC) (July 2009). "Summary of Notifiable Diseases --- United States, 2007" (PDF). MMWR Morb. Mortal. Wkly. Rep. 56 (53).
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
- Bloch AB, Orenstein WA, Stetler HC, et al. (1985). "Health impact of measles vaccination in the United States". Pediatrics. 76 (4): 524–32. PMID 3931045.
- Centers for Disease Control and Prevention (CDC) (March 2006). "Progress in reducing global measles deaths, 1999–2004" (PDF). MMWR Morb. Mortal. Wkly. Rep. 55 (9): 247–9. PMID 16528234.
- "Measles Fact Sheet #286". World Health Organization (WHO). Retrieved 1 December 2014.
- Parker AA, Staggs W, Dayan GH, Ortega-Sánchez IR, Rota PA, Lowe L, Boardman P, Teclaw R, Graves C, LeBaron CW (2006). "Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States". N Engl J Med. 355 (5): 447–55. doi:10.1056/NEJMoa060775. PMID 16885548. S2CID 34529542.
- Centers for Disease Control and Prevention (CDC) (December 2006). "Measles—United States, 2005" (PDF). MMWR Morb. Mortal. Wkly. Rep. 55 (50): 1348–51. PMID 17183226.
- Hall V, Banerjee E, Kenyon C, Strain A, Griffith J, Como-Sabetti K, Heath J, Bahta L, Martin K, McMahon M, Johnson D, Roddy M, Dunn D, Ehresmann K (July 2017). "Measles Outbreak — Minnesota April–May 2017" (PDF). MMWR Morb. Mortal. Wkly. Rep. 66 (27): 713–717. doi:10.15585/mmwr.mm6627a1. ISSN 0149-2195. PMC 5687591. PMID 28704350.
- "Rubella vaccine information". National Network for Immunization Information. 2006-09-25. Archived from the original on 2007-09-27. Retrieved 2007-09-02.
- Jequier AM (2000). Male infertility: a guide for the clinician. Malden, MA: Blackwell Publishing. p. 118. ISBN 978-0-632-05129-8.
- Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A (2007). "Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine". Pediatr Infect Dis J. 26 (7): 632–8. doi:10.1097/INF.0b013e3180616c8f. PMID 17596807. S2CID 41981427.
- "MMR vaccine questions and answers". Centers for Disease Control and Prevention (CDC). 2004. Archived from the original on July 25, 2008. Retrieved 2008-05-28.
- Harnden A, Shakespeare J (2001). "10-minute consultation: MMR immunisation". BMJ. 323 (7303): 32. doi:10.1136/bmj.323.7303.32. PMC 1120664. PMID 11440943.
- Thompson GR, Ferreyra A, Brackett RG (1971). "Acute Arthritis Complicating Rubella Vaccination" (PDF). Arthritis & Rheumatism. 14 (1): 19–26. doi:10.1002/art.1780140104. hdl:2027.42/37715. PMID 5100638.
- Schattner A (2005). "Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines". Vaccine. 23 (30): 3876–86. doi:10.1016/j.vaccine.2005.03.005. PMID 15917108.
- Carapetis JR, Curtis N, Royle J (2001). "MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare". BMJ. 323 (7317): 869. doi:10.1136/bmj.323.7317.869a. PMC 1121404. PMID 11683165.
- Fox A, Lack G (October 2003). "Egg allergy and MMR vaccination". Br J Gen Pract. 53 (495): 801–2. PMC 1314715. PMID 14601358. Archived from the original on 2013-01-26.
- "Approval for label change".
- Medicine Io, Practice Bo, Vaccines Ct, Ford A, Rusch E, Clayton EW (26 March 2012). Adverse Effects of Vaccines. nap.edu. doi:10.17226/13164. ISBN 978-0-309-21435-3. PMID 24624471.
- Institute of Medicine (1994). "Measles and mumps vaccines". Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. National Academy Press. ISBN 978-0-309-07496-4.
- Colville A, Pugh S, Miller E, Schmitt HJ, Just M, Neiss A (1994). "Withdrawal of a mumps vaccine". Eur J Pediatr. 153 (6): 467–8. doi:10.1007/BF01983415. PMID 8088305. S2CID 43300463.
- Fullerton KE, Reef SE (2002). "Commentary: Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control". Int J Epidemiol. 31 (5): 983–4. doi:10.1093/ije/31.5.983. PMID 12435772.
- Sauvé LJ, Scheifele D (January 2009). "Do childhood vaccines cause thrombocytopenia?". Paediatr Child Health. 14 (1): 31–2. doi:10.1093/pch/14.1.31. PMC 2661332. PMID 19436461.
- Black, C., Kaye, J. A. and Jick, H. (2003). "MMR vaccine and idiopathic thrombocytopaenic purpura". British Journal of Clinical Pharmacology. 55 (1): 107–111. doi:10.1046/j.1365-2125.2003.01790.x. PMC 1884189. PMID 12534647.CS1 maint: multiple names: authors list (link)
- Wakefield A, Murch S, Anthony A; et al. (1998). "Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children". Lancet. 351 (9103): 637–41. doi:10.1016/S0140-6736(97)11096-0. PMID 9500320. S2CID 439791. Retrieved 2007-09-05.CS1 maint: multiple names: authors list (link) (Retracted)
- Cassandra Jardine (29 Jan 2010). "GMC brands Dr Andrew Wakefield 'dishonest, irresponsible and callous'". The Telegraph. London. Retrieved 31 January 2015.
- The Editors Of The Lancet (February 2010). "Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children". Lancet. 375 (9713): 445. doi:10.1016/S0140-6736(10)60175-4. PMID 20137807. S2CID 26364726. Lay summary – BBC News (2010-02-02).
- "General Medical Council, Fitness to Practise Panel Hearing, 24 May 2010, Andrew Wakefield, Determination of Serious Professional Misconduct" (PDF). General Medical Council. Archived from the original (PDF) on 9 August 2011. Retrieved 18 September 2011.
- Meikle J, Boseley S (24 May 2010). "MMR row doctor Andrew Wakefield struck off register". The Guardian. London. Archived from the original on 27 May 2010. Retrieved 24 May 2010.
- Godlee F, Smith J, Marcovitch H (2011). "Wakefield's article linking MMR vaccine and autism was fraudulent". BMJ. 342 (jan05 1, c7452): c7452. doi:10.1136/bmj.c7452. PMID 21209060. S2CID 43640126.
- National Health Service (2004). "MMR: myths and truths". Archived from the original on 2008-09-13. Retrieved 2007-09-03.
- "Measles, mumps, and rubella (MMR) vaccine". Centers for Disease Control and Prevention. 2008-08-22. Archived from the original on 2008-10-08. Retrieved 2008-12-21.
- Immunization Safety Review: Vaccines and Autism Archived 2007-06-23 at the Wayback Machine. From the Institute of Medicine of the National Academy of Sciences. Report dated May 17, 2004; accessed June 13, 2007.
- MMR Fact Sheet Archived 2007-06-15 at the Wayback Machine, from the United Kingdom National Health Service. Accessed June 13, 2007.
- MMR vs three separate vaccines:
- Halsey NA; Hyman SL; Conference Writing Panel (2001). "Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12–13, 2000". Pediatrics. 107 (5): e84. doi:10.1542/peds.107.5.e84. PMID 11331734.
- Leitch R, Halsey N, Hyman SL (2002). "MMR—Separate administration-has it been done?". Pediatrics. 109 (1): 172. doi:10.1542/peds.109.1.172. PMID 11773568.
- Miller E (2002). "MMR vaccine: review of benefits and risks". J Infect. 44 (1): 1–6. doi:10.1053/jinf.2001.0930. PMID 11972410.
- "Doctors issue plea over MMR jab". BBC News. 2006-06-26. Retrieved 2009-02-04.
- Thomas J (2010). "Paranoia strikes deep: MMR vaccine and autism". Psychiatric Times. 27 (3): 1–6. Archived from the original on 2015-04-09.
- Honda H, Shimizu Y, Rutter M (2005). "No effect of MMR withdrawal on the incidence of autism: a total population study". J Child Psychol Psychiatry. 46 (6): 572–9. CiteSeerX 10.1.1.579.1619. doi:10.1111/j.1469-7610.2005.01425.x. PMID 15877763. Lay summary – Bandolier (2005).
- Plotkin SA, Vaheri A (1967). "Human fibroblasts infected with rubella virus produce a growth inhibitor". Science. 156 (3775): 659–61. Bibcode:1967Sci...156..659P. doi:10.1126/science.156.3775.659. PMID 6023662. S2CID 32622296.
- Hayflick L, Moorhead PS (1967). "The serial cultivation of human diploid cell strains". Exp. Cell Res. 25 (3): 585–621. doi:10.1016/0014-4827(61)90192-6. PMID 13905658.
- "Attenuvax Product Sheet" (PDF). Merck & Co. 2006. p. 1. Archived from the original (PDF) on 2009-12-31. Retrieved 2009-02-04.
- Merck Co. (2002). "MUMPSVAX (Mumps Virus Vaccine Live) Jeryl Lynn Strain" (PDF). Merck Co. Archived from the original (PDF) on 2006-08-13. Retrieved 2015-01-26.
- Young ML, Dickstein B, Weibel RE, Stokes J Jr, Buynak EB, Hilleman MR (1967). "Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic". Pediatrics. 40 (5): 798–803. PMID 6075651.
- Reef, Susan E.; Plotkin, Stanley A. (2018). "Rubella Vaccines". Plotkin's Vaccines. pp. 970–1000.e18. doi:10.1016/B978-0-323-35761-6.00052-3. ISBN 9780323357616.
- Böröcz, K.; Csizmadia, Z.; Markovics, Á.; Farkas, N.; Najbauer, J.; Berki, T.; Németh, P. (2020). "Application of a fast and cost-effective 'three-in-one' MMR ELISA as a tool for surveying anti-MMR humoral immunity: The Hungarian experience". Epidemiology and Infection. 148: e17. doi:10.1017/S0950268819002280. PMC 7019553. PMID 32014073.
- Klein NP, Yih WK, Marin M, et al. (March 2008). "Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine" (PDF). MMWR Morb. Mortal. Wkly. Rep. 57 (10): 258–60. PMID 18340332.
- O'Leary ST, Suh CA, Marin M (Nov 2012). "Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think?". Vaccine. 30 (48): 6731–3. doi:10.1016/j.vaccine.2012.08.075. PMID 22975026.
- Pager T (9 April 2019). "'Monkey, Rat and Pig DNA': How Misinformation Is Driving the Measles Outbreak Among Ultra-Orthodox Jews". The New York Times. Retrieved 14 April 2019.
- "Vaccines and porcine gelatine" (PDF). Public Health England. August 2015. Retrieved 14 April 2019.
- World Health Organization (January 2009). The immunological basis for immunization series: module 7: measles (update 2009). World Health Organization (WHO). hdl:10665/44038. ISBN 9789241597555.
- World Health Organization (November 2010). The immunological basis for immunization series: module 16: mumps. World Health Organization (WHO). hdl:10665/97885. ISBN 9789241500661.
- World Health Organization (December 2008). The immunological basis for immunization series: module 11: rubella. World Health Organization (WHO). hdl:10665/43922. ISBN 9789241596848.
- Ramsay M, ed. (December 2019). "Chapter 21: Measles". Immunisation against infectious disease. Public Health England.
- Ramsay M, ed. (April 2013). "Chapter 23: Mumps". Immunisation against infectious disease. Public Health England.
- Ramsay M, ed. (April 2013). "Chapter 28: Rubella". Immunisation against infectious disease. Public Health England.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 13: Measles". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 15: Mumps". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 20: Rubella". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC). ISBN 978-0990449119.
- Roush SW, Baldy LM, Hall MA, eds. (March 2019). "Chapter 7: Measles". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention (CDC).
- Roush SW, Baldy LM, Hall MA, eds. (March 2019). "Chapter 9: Mumps". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention (CDC).
- Roush SW, Baldy LM, Hall MA, eds. (March 2019). "Chapter 14: Rubella". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention (CDC).